Purpose: Limited data regarding the cystic fibrosis carrier frequency and mutation detection rate is available for Arab-Americans. We retrospectively determined the frequency of carriers among Arab-Americans undergoing preconception and prenatal carrier screening in our laboratories. Methods: Between October, 2001 and June, 2005, we performed carrier screening on 805 Arab-Americans, testing for at least the original 25 mutations recommended by the American College of Medical Genetics. We compared our results to previously published studies among Arabic cystic fibrosis patients. We also performed diagnostic testing on seven individuals.
Since the cloning of the cystic fibrosis (CF) gene in 1989, 1,2,3 more than 1,000 mutations have been identified. 4 Most are extremely rare, often reported in only one family. In 2001, the American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists (ACOG) recommended CF carrier screening using a 25-mutation panel for Caucasians who are pregnant or considering pregnancy. They also recommended that testing be made available to individuals in other races and ethnic groups with a lower CF carrier frequency. 5 The original 25 mutations were chosen because they had a frequency of Ն0.1% in the pan-ethnic U.S. population. 5 This panel was modified in 2004 to 23 mutations. 6 Reliable data exist for the carrier frequency and mutation detection rates among Caucasians, African-Americans, and Hispanic-Americans. This is essential for accurate interpretation and risk assessment used by patients to make informed decisions regarding reproductive options. 6, 7 However, there is limited epidemiological data on the frequency of CF and prevalent mutations among Arabic CF patients. Furthermore, there are no published reports describing the outcome of CF carrier screening among Arab-Americans. Detroit, Michigan has one of the largest Arab-American populations. Arab-Americans comprise the third largest population tested in our laboratories, after Caucasians and African-Americans. We report our experience with CF carrier screening among Arab-Americans and compare our results to previously published studies among Arabic CF patients.
MATERIALS AND METHODS

Patient population
Since January, 1990, we performed diagnostic testing on seven Arab-American patients, six with a suspected diagnosis of CF and one with congenital bilateral absence of the vas deferens (CBAVD) ( Table 1) . Between October, 2001 and June, 2005, a total of 805 individuals of self-reported Arab-American ancestry (including Arabic, Chaldean, Iraqi, Syrian, Jordanian, and Lebanese) underwent CF carrier screening at our institutions. The indications for testing were population carrier screening for 757 (94%) individuals. The remaining 48 patients included in this report were tested for an unspecified indication, assumed to be carrier screening because they were pregnant females and the test was ordered by an obstetrician or nurse midwife. Of the patients tested, 784 (97%) were female and 21(3%) were male. Five couples were tested in a sequential manner, with the remaining 16 tested simultaneously.
Molecular CF mutation analysis
DNA was extracted using either the PureGene kit (Gentra) or QIAmp DNA Blood Mini Kit (Qiagen) according to the conditions specified by the manufacturers. Several methods were used for CF mutation analysis throughout this time period by the two laboratories; all methods used for carrier screening included the original 25 mutations recommended by ACOG/ACMG.
Method A
Prior to October, 2001, CF studies were performed by PCR amplification followed by heteroduplex analysis (exons 3, 4, 5, 7, 10, 11 and 19) on a mutation detection enhancement (MDE) gel and restriction fragment length polymorphisms (RFLP) analysis for specific mutations. This method was used only for diagnostic testing and was not used for any preconception or prenatal carrier screening. DNA sequencing was used to confirm mutations identified by heteroduplex analysis when no confirmatory RFLP was available. Mutations tested were: 297-3CϾT, G85E, 394delTT, P67L,405ϩ3AϾC,E92X,556delA,557delT,I148T,R117H,A120T, Y122X, 621 ϩ 1GϾT, G178R, 711 ϩ 1GϾT, R297Q, Y301C, R347P, R334W, ⌬F311, 1078delT, 1138insG, 1154insTC, I1336K, A455E, ⌬F508, ⌬I507, Q493X, V520F, 1548delG, 1609delCA, 1677delTA, 1717-1GϾA,G551D,R553X,R560T,G542X,G551S,S549N,S549R, 1891 ϩ 1GϾA, 2189delA, 2789 ϩ 5GϾA, 3120 ϩ 1GϾA, 3659delC, R1162X, S1235R, I1234V, 3849 ϩ10kbCϾT, W1282X and N1303K. Additional mutations would theoretically also be detected by heteroduplex analysis.
Method B
Between October, 2001 and August, 2002, 115 individuals were screened using a combination of the CF OLA v2.0 kit (Celera Diagnostics/Abbot Diagnostics/Applied Biosystems) to test for 31 CF mutations including additional nine mutations (Q493X, V520F, S549N, S549R, 3849 ϩ 4A¡G, 3905insT, Y122X, R347H, and 2183AA¡G) that were not in the ACMG recommended panel, a laboratory-developed heteroduplex analysis (exon 4 and 13) and RFLP analysis for three additional recommended muta-tions, but not included in CF OLA v2.0 (I148T, 2184delA, and 3120 ϩ 1G¡A, respectively).
Method C
Between September, 2002 and June, 2005, 645 individuals were tested using the CF OLA v3.0 ASR kit, which includes all 25 recommended mutations (eliminating the need for additional testing using alternative methods) in addition to seven other CF mutations (S549N, S549R, V520F, 3876delA, 394delTT, 3905insT, and R347H). Detection of all OLA products was performed using an ABI 3100 Genetic Analyzer (capillary sequencer) followed by analysis using GeneScan and Genotyper software (Applied System).
Method D
Forty-five individuals were tested using the INNO-LiPA CFTR Assay System (reverse dot blot hybridization). This assay uses PCR-derived amplicons, which hybridize to two test strips that contain 74 probes and four control lines. Included on the strips are the mutant and wild-type sequences of 36 immobilized targets covering ACMG recommended mutations and 11 additional CF mutations (CFTRdele2, 3(21kb), 3272-26A¡G, 3905insT, S1251N, 3199del6, Q552X, 2183AA¡G, 394delTT, 2143delT, E60X, 711 ϩ 5G¡A).
Reflex testing for 3199del6 on I148T carriers was done using a laboratory-developed heteroduplex assay. The length of the intron 8 polyT tract was determined for R117H carriers using a previously described method. 8 
RESULTS
We identified a total of seven CF carriers among the 805 Arab-Americans screened, for an overall observed carrier fre- quency of 1/115 (0.9%). Thirteen I148T carriers were also identified; however, because they did not have 3199del6, they were not considered to be CF carriers in our analysis. 9, 10 We identified four W1282X carriers, two ⌬F508 carriers, and one R117H/7T carrier who also had I148T but was negative for 3199del6. The overall observed allele frequencies for W1282X, ⌬F508, and R117H were 0.25%, 0.12% and 0.06%, respectively.
We identified one positive-positive consanguineous couple through sequential screening; both were W1282X carriers. Fetal testing done by CVS revealed homozygosity for W1282X, and the fetus was predicted to be affected with CF. This pregnancy was terminated after the couple received genetic counseling. Because this couple was tested sequentially and was known to be consanguineous, the W1282X carrier status of the male partner was not included in our calculations to determine carrier frequency in the Arab-American population.
Genotype results for patients tested for diagnostic purposes are summarized in Table 1 . Among 6 patients with a known or suspected diagnosis of CF, 2 had 2 identifiable mutations and one carried only one copy of 5T. Two mutations were also identified in an adult male with CBAVD. The mutations identified among this group included 1548delG (2 chromosomes), ⌬F508, W1282X, 2789 ϩ 5GϾA and R170H (1 chromosome, each).
DISCUSSION
In this study, a total of 805 individuals of self-reported Arab-American ancestry underwent CF carrier screening. We identified seven CF carriers, with an observed carrier frequency of 1 in 115. Compared to other populations, the observed carrier frequency among Arab-Americans is lower than African-Americans and Hispanic-Americans (Table 2) . 5, 6, 7 One previously published study estimated the incidence of CF among Arabic children as 1 in 4,243, 11 representing a carrier frequency of 1 in 33. Although we are unaware of any published data regarding CF population carrier screening among Arab-Americans, several studies have reported the mutation distribution among Arabic CF patients. 12, 13, 14 Combin-ing these studies, a total of 96 CF patients from 93 different Arabic families were analyzed. Among the 93 different families, 26 different mutations were identified with the results summarized in Table 3 . Of these mutations, ⌬F508, 1548delG, 3120 ϩ 1G¡A, I1234V, N1303K, W1282X, H139L, 4010del4, G115X, 711 ϩ 1G¡A and S549R are the most common, together accounting for 70% of CF chromosomes in this population. In addition, a large deletion of exons 17a, 17b and 18 (3120 ϩ 1Kbdel8.6Kb) has been reported in Israeli Arab CF patients. 15 Due to the methods used in our laboratories, we would not have detected this mutation among our patients. Although we have tested a small number of affected CF patients, our findings are consistent with 1548delG, ⌬F508, and W1282X as common Arabic CF mutations. The mutations included in the current ACMG CF mutation screening panel Genetic screening for CF is performed to provide an individual or couple with information regarding their risk of having a child with CF. Individuals with a negative result after CF carrier testing have a residual carrier risk calculated using a Bayesian analysis, which takes into account the population carrier frequency and mutation detection rate in the individual's race or ethnic background. These calculations can be performed for several populations, namely Caucasian, African-American, Hispanic, and Asian. Because the CF carrier frequency and mutation detection rate has not been well-established among the Arab-American population, no accurate residual risk can be provided to these individuals following a negative CF mutation screen. An additional challenge when counseling these patients arises due to the high incidence of consanguinity among this population, which increases the occurrence of autosomal recessive genetic diseases, such as CF. It is necessary to improve the interpretation of negative CF carrier screening results in this group to provide individuals with accurate information so that they can make informed reproductive decisions. Supplementation of the existing CF mutation panel has been suggested for other populations including African-Americans 16 and Hispanic-Americans, 17 and may also be helpful to laboratories screening a large number of Arab-Americans.
